Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05800132 | Diagnostic Performance of Breast Cancer Screening Second Reading Process Assisted by AI(IMA-L2) | recruiting | N/A | 5,000 | TherapixelINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06341621 | Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib(Rainbow) | recruiting | Phase 3 | 1,900 | Fudan UniversityOTHER | 1 | Apr 10, 2024 |
| clinicaltrials |
| NCT06354114 | A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011 | not yet recruiting | Phase 2 | 80 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT02240836 | Energy Balance and Breast Cancer Aspects-II(EBBA-II) | active not recruiting | N/A | 545 | Oslo University HospitalOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03281954 | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo | active not recruiting | Phase 3 | 1,550 | NSABP Foundation IncNETWORK | 2 | Apr 8, 2024 | clinicaltrials |
| NCT06334471 | Whole Genome Sequencing in Breast Cancer(WGS SIT) | recruiting | — | 1,200 | Inocras Korea Inc.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06340516 | NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity | recruiting | N/A | 700 | Vastra Gotaland RegionOTHER_GOV | 1 | Apr 1, 2024 | clinicaltrials |
| NCT01996267 | Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2(TRAIN-2) | active not recruiting | Phase 3 | 437 | The Netherlands Cancer InstituteOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT05986071 | I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers(MATRIX) | not yet recruiting | Phase 1 / Phase 2 | 57 | Institut Paoli-CalmettesOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT06330012 | The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients. | recruiting | N/A | 50 | Samsung Medical CenterOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06330870 | Brain Metastasis Development Mechanism in BCBM Patients | recruiting | N/A | 30 | Samsung Medical CenterOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT05433753 | Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study | recruiting | — | 60 | National Cancer Center, JapanOTHER_GOV | 1 | Mar 25, 2024 | clinicaltrials |
| NCT05861271 | Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer | recruiting | Phase 2 | 1,008 | Fudan UniversityOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT02474641 | Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer(HYPOSIB) | active not recruiting | N/A | 2,324 | University Hospital Schleswig-HolsteinOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06321653 | Lymphedema Evaluation After Adjuvant Hypofractionated Radiotherapy for 1-2 Macrometastatic Sentinel Lymph Nodes(AXILL-ART) | recruiting | — | 120 | European Institute of OncologyOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06227117 | Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer | recruiting | Phase 2 | 120 | RemeGen Co., Ltd.INDUSTRY | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06315868 | Breast Cancer Subtype Characterization Through Patient's Derived Organoids.(BCinsightPDO) | recruiting | — | 306 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06202261 | A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 154 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06307249 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA) | recruiting | Phase 1 | 50 | Lebanese UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03595592 | Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer(APTneo) | active not recruiting | Phase 3 | 650 | Fondazione MichelangeloOTHER | 4 | Mar 6, 2024 | clinicaltrials |
| NCT05370300 | SNAPS Breast Cancer Patient Study Breast Cancer Patients | not yet recruiting | — | 500 | Immunis.AIINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05789901 | The MARVIN Chatbots to Provide Information for Different Health Conditions | recruiting | N/A | 400 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05441943 | Lymphaticovenous Anastomosis as Treatment for Lymphedema | active not recruiting | N/A | 10 | Odense University HospitalOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT05698056 | A Retrospective Analysis of Magnetic Resonance Imaging Data for Breast Cancer Screening in the Open Consortium for Decentralized Medical Artificial Intelligence(ODELIA) | active not recruiting | — | 25,000 | Technische Universität DresdenOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06195371 | Impact of CASP3 Gene in Chemoresistance | not yet recruiting | — | 60 | Gehad Salah El-Din shakerOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT06217185 | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | recruiting | Phase 4 | 100 | Hebei Medical University Fourth HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06270355 | Stockholm Mammography Risk Stratified Trial(SMART) | not yet recruiting | Phase 3 | 70,000 | Karolinska InstitutetOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT06281145 | Stress-Reducing Intervention in Patients With Colorectal and Breast Cancer(SRI-BrCa_CRC) | recruiting | N/A | 100 | Comenius UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06281210 | Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery(BETTY-CRASY) | recruiting | N/A | 77 | European Institute of OncologyOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06282796 | Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy | recruiting | — | 600 | First Hospital of China Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06266026 | ThermoBreast - Non-contact Breast Cancer Imaging Using AI-enhanced Thermography.(ThermoBreast) | recruiting | N/A | 28,000 | ThermoMind Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06268327 | Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy | not yet recruiting | Phase 2 / Phase 3 | 30 | Assiut UniversityOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT06268652 | Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer | recruiting | Phase 3 | 302 | Sun Yat-sen UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06259162 | LAG3 Expression in Triple Negative Breast Cancer | recruiting | N/A | 128 | Samsung Medical CenterOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT06259513 | Omission of Axillary Surgery in Breast Cancer Patients | recruiting | N/A | 350 | KK Women's and Children's HospitalOTHER_GOV | 1 | Feb 14, 2024 | clinicaltrials |
| NCT06254690 | The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study | recruiting | Phase 2 | 102 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05891093 | Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | recruiting | Phase 3 | 766 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05949541 | Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer(BCTOP-L-M01) | recruiting | Phase 2 | 265 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06245824 | Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial | not yet recruiting | Phase 4 | 51 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT02839863 | Utrecht Cohort for Multiple Breast Cancer Intervention Studies and Long-term Evaluation - The UMBRELLA Cohort(UMBRELLA) | recruiting | — | 10,000 | UMC UtrechtOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05760378 | Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. | recruiting | Phase 3 | 223 | Fudan UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05159193 | Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer | recruiting | Phase 3 | 372 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06229067 | Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 182 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 29, 2024 | clinicaltrials |
| NCT05746897 | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 38 | Hefei TG ImmunoPharma Co., Ltd.OTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06169072 | Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients(MagSnow2) | recruiting | Phase 2 | 220 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT02641847 | TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature | active not recruiting | Phase 2 / Phase 3 | 503 | Fudan UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 12, 2024source: clinicaltrials